The NIFTY® (Non-Invasive Fetal Trisomy) test is a prenatal DNA test. Cell free fetal DNA, circulates into the mother’s blood stream, and is analyzed in order to examine the baby’s health. This analysis is highly accurate and safe for mother and baby, and measures the risk for trisomies 21, 18 and 13 with a sensitivity and specificity rate of over 99%*. We also offer additional testing options for certain sex chromosomal aneuploidies and microdeletion syndromes. The test is available as early as week 10 of pregnancy, regardless if it’s a single or twin pregnancy, or a fetal resorption (vanishing twin- one twin deceased in utero). This type of prenatal test is recommended by the SOGC (Society of Obstetricians and Gynecologists of Canada), in order to avoid an invasive amniocentesis (1). Speak with your physician to learn if a NIFTY® test is right for you.

Two options are available for the NIFTY® :

The NIFTY® option is available from week 10 of pregnancy for a singleton or twin pregnancy.  This option includes analysis of chromosomal abnormalities, and microdeletions

The NIFTYPRO® option is available from week 10 of pregnancy for a singleton pregnancy.  This option includes analysis of chromosomal abnormalities, microdeletions and DiGeorge syndrome. 

*In the case of sex determination this must be written on the health care professionals prescription.  

NIFTY® is now available to be drawn directly at your home or place of employment, appointments are available days, evenings and weekend**.  Fees for travel to your location apply and are calculated based on distance travelled.  Contact us directly at 1-888-PROCREA for more information and to book your appointment.

Click here to view Prenatal Screening Comparison. 

Find a NIFTY Blood Center:
British Columbia
New Brunswick
Prince Edward Island
Quebec – BIron Centers

*For more information, visit:

**At home blood draws available in select regions.  Appointment days and times also vary by region.

NIFTY® is a registered trademark of BGI.

Clinical validation : Non invasive Prenatal testing for Trisomy 21, 18 and 13 – Clinical Experience from 146,958 Pregnancies

NIFTY brochure

(1) SOGC Committee Opinion 2013, #287
(2) Current Status in Non-Invasive Prenatal Detection of Down Syndrome, Trisomy 18, and Trisomy 13 Using Cell-Free DNA in Maternal Plasma